NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks
NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting regulatory advancement as global cases rise.
NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of measles, a move that provides potential incentives including tax credits, fee exemptions, and market exclusivity. The designation is expected to support the regulatory advancement of NV-387, which has demonstrated in vivo activity against measles and is being developed to address rising global outbreaks.
Orphan Drug Designation is granted by the FDA to drugs intended to treat rare diseases affecting fewer than 200,000 people in the United States. For NanoViricides, this designation not only offers financial incentives but also positions NV-387 for a potentially faster path to market. The company emphasized that the designation underscores the drug's potential to address a significant unmet medical need, particularly as measles cases have been surging worldwide due to declining vaccination rates.
NV-387 is a broad-spectrum antiviral drug candidate that the company is developing for multiple viral infections, including respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections. According to the company, NV-387 has also shown effectiveness in animal models for monkeypox, smallpox, and measles. The drug's broad-spectrum activity is a key differentiator, as it targets a wide range of viruses, potentially offering a versatile tool in combating emerging viral threats.
The company's press release notes that NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The successful completion of Phase I without safety concerns provides a strong foundation for the next stages of development.
Dr. Anil Diwan, President and Executive Chairman of NanoViricides, commented, "We are extremely pleased to receive Orphan Drug Designation for NV-387 for the treatment of measles. This designation is a significant milestone for the company and highlights the potential of our broad-spectrum antiviral platform to address serious viral diseases." The company's press release, available at https://ibn.fm/uIWWv, provides additional details on the announcement.
The implications of this designation are far-reaching. For NanoViricides, it provides a clear regulatory pathway and potential financial benefits that could accelerate the development timeline. For public health, the development of an effective antiviral for measles could be a game-changer in controlling outbreaks, especially in regions where vaccination coverage is insufficient. Measles remains a leading cause of death among young children globally, despite the availability of a safe and effective vaccine.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a unique broad-spectrum antiviral that the company plans to develop for multiple indications. The company's other advanced drug candidate, NV-HHV-1, targets all herpesvirus infections including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV (shingles), and chickenpox.
More information about NanoViricides and its pipeline can be found on its website at http://www.nanoviricides.com. Investors can access the latest news and updates relating to NNVC in the company’s newsroom at https://ibn.fm/NNVC.